[855] 4MY-BEAR (469-2327) [email protected]

GENETIC TESTING

Medication Management

Dementia, Alzheimer’s, Parkinson’s Disease (DAP)

Diagnosing hereditary Dementias, Alzheimer’s and or Parkinson’s disease.

The purpose of this test is to identify a pathogenic or likely pathogenic mutation(s) in genes that have been associated with hereditary forms of Dementia, Alzheimer’s disease and/or Parkinson’s disease.

Dementia, Alzheimers and Parkinson's Testing

Genetic Analysis

Analyzes 34 genes with dominant, recessive, and X-linked inheritance patterns.

Everything you need

Buccal swab test packet provided for easy collection and return to the lab. Return shipping and or courier is included.

Quick Online Results

Results available in three weeks. Online result reporting through our HIPAA compliant portal.

Genetic Counseling Available

Genetic Counseling is offered as an additional service.

Description

The clinical spectrum of hereditary forms of Dementia and Parkinson’s is broad. Genetic testing can confirm a suspected clinical diagnosis or rule out diagnoses with a similar clinical presentation. Individuals considering genetic testing for hereditary forms of Dementia, Alzheimer’s and/or Parkinson’s disease should first receive thorough pre-test genetic counseling from a professional qualified to provide such counseling regarding the implications of testing for neurodegenerative disorders that have no known treatment or cure at this time.

This panel covers genes with dominant, recessive, and X-linked inheritance patterns, and may be helpful in clarifying recurrence risk and determining which relatives may be at risk, particularly if the inheritance pattern is unclear from an individual’s family history.

Results of this genetic test will help determine the diagnosis so that the physician can proceed with the proper treatment and management necessary by:

  • Enabling clinicians to establish a specific diagnosis that can put an end to the quest (often lengthy and costly) for an accurate diagnosis.
  • Facilitate early detection and treatment of symptoms.
  • Counseling will be far more targeted regarding prognosis.
  • Elimination of the ongoing cost of further low-specificity and low sensitivity testing that is often repeated many times and is expensive (brain MRI, biomarker testing, etc).
  • Choice of appropriate therapy. For example, the list of treatable forms of Parkinson’s continues to grow. In the case of dopa-responsive PD and dystonia-parkinsonism, administration of levodopa can produce excellent and sustained responses.
  • Promote enrollment in clinical trials.